H.C. Wainwright analyst Swayampakula Ramakanth raised the firm's price target on Corcept Therapeutics to $95 from $75 and keeps a Buy rating on the shares. The firm cites the company's "positive" relacorilant update and clarity on the regulatory pathway for the target boost. The new drug application resubmission raises the probability for approval of a second indication for relacorilant, the analyst tells investors in a research note.
